Quick Takeaways
- BlackRock, Inc. filed SCHEDULE 13G/A for BIOCRYST PHARMACEUTICALS INC Common Stock (BCRX).
- Disclosed ownership: 8.4%.
- Date of event: 31 Mar 2025.
BlackRock, Inc. - 31 Mar 2025 SCHEDULE 13G/A Report for BIOCRYST PHARMACEUTICALS INC Common Stock (BCRX)
- Filing Manager
- BlackRock, Inc.
- Reporting Manager
- BlackRock, Inc.
- Symbol
- BCRX
- Shares outstanding
- 208,136,786 shares
- Disclosed Ownership
- 17,483,490 shares
- Ownership
- 8.4%
- Form type
- SCHEDULE 13G/A
- Filing time
- 17 Apr 2025, 09:35:27 UTC
- Date of event
- 31 Mar 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"BlackRock, Inc. disclosed 8.4% ownership in BIOCRYST PHARMACEUTICALS INC Common Stock (BCRX) on 31 Mar 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 17 Apr 2025, 09:35.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 8.4% | 17,483,490 | 17,252,025 | 0 | Spencer Fleming | Managing Director |